Changchun BCHT Biotechnology Co
SSE:688276
Changchun BCHT Biotechnology Co
Changchun BCHT Biotechnology Co. engages in the research and development, production and sale of human vaccines. The company is headquartered in Changchun, Jilin and currently employs 1,252 full-time employees. The company went IPO on 2021-06-25. The firm is mainly engaged in the research and development, production and sales of human vaccines. The firm has three approved vaccine products: varicella vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine. The firm also has other vaccines under development and fully human monoclonal antibody under development for the prevention and control of infectious diseases. The firm mainly conducts business within the domestic market.
Changchun BCHT Biotechnology Co. engages in the research and development, production and sale of human vaccines. The company is headquartered in Changchun, Jilin and currently employs 1,252 full-time employees. The company went IPO on 2021-06-25. The firm is mainly engaged in the research and development, production and sales of human vaccines. The firm has three approved vaccine products: varicella vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine. The firm also has other vaccines under development and fully human monoclonal antibody under development for the prevention and control of infectious diseases. The firm mainly conducts business within the domestic market.
